Perspectum Ltd
AI-driven quantitative MRI imaging software and services (e.g., LiverMultiScan) for clinicians, hospitals and pharma trials in liver, metabolic and related diseases.
Perspectum, an Oxford University spin-out, develops AI-powered medical imaging and data-analysis tools. Its best-known product is LiverMultiScan, a non-invasive MRI-based assessment of liver disease, and it also covers metabolic disease, diabetes and cancer. It sells software and imaging services to clinicians and healthcare providers, and runs clinical-trial imaging services for pharma. It raised a $55M Series C led by Oppenheimer, closing in March 2023, and Tracxn estimates roughly $140M raised in total. Tracxn also puts 2024 revenue in the £10–50M range, and headcount is about 260–280 (2026).
